RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Design, synthesis, and analysis of antagonists of GPR55
Piperidine-substituted 1,3,4-oxadiazol-2-ones
Meza-Avina, M. E., Lingerfelt, M. A., Console-Bram, L. M., Gamage, T. F., Sharir, H., Gettys, K. E., Hurst, D. P., Kotsikorou, E., Shore, D. M., Caron, M. G., Rao, N., Barak, L. S., Abood, M. E., Reggio, P. H., & Croatt, M. P. (2016). Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorganic and Medicinal Chemistry Letters, 26(7), 1827-1830. https://doi.org/10.1016/j.bmcl.2016.02.030
A series of 1,3,4-oxadiazol-2-ones was synthesized and tested for activity as antagonists at GPR55 in cellular beta-arrestin redistribution assays. The synthesis was designed to be modular in nature so that a sufficient number of analogues could be rapidly accessed to explore initial structure-activity relationships. The design of analogues was guided by the docking of potential compounds into a model of the inactive form of GPR55. The results of the assays were used to learn more about the binding pocket of GPR55. With this oxadiazolone scaffold, it was determined that modification of the aryl group adjacent to the oxadiazolone ring was often detrimental and that the distal cyclopropane was beneficial for activity. These results will guide further exploration of this receptor. (C) 2016 Elsevier Ltd. All rights reserved.